Search results
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Kyowa Kirin Asia Pacific is a Japan-based Global Specialty Pharmaceutical Company that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Through a robust pipeline of promising drug candidates, pharmaceutical innovator Kyowa Kirin aims to ensure people around the world have access to safe, effective treatment. This page describes the company's research, technologies, and development schedules.
Kyowa Kirin International develops and commercializes innovative prescription medicines for unmet medical needs. Explore our portfolio and commitment to improving patient lives.
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue.
May 14, 2024 · With over 500 people focused on this purpose we've become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of unmet therapeutic needs. Kyowa Kirin International plc is owned by Kyowa Kirin Co., Ltd. of Japan.
Kyowa Kirin Co., Ltd. | 8,980 followers on LinkedIn. Kyowa Kirin strives to create and deliver novel medicines with life-changing value.
May 31, 2024 · This is the Kirin Holdings Kyowa Kirin page under the Pharmaceuticals domain page. It includes the specific business activities and product brands in the three main domains of the Kirin Group (Food & Beverages, Health Science and Pharmaceuticals).
Kyowa Kirin is a global specialty pharmaceutical company delivering life-changing value for people impacted by under-diagnosed and under-served diseases. Our Commitment to Life means that we are focussing our efforts to improve the quality of life for patients around the world with high unmet medical needs.
Jan 1, 2024 · Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice. Kyowa Kirin R&D Meeting. December 11, 2023. （3,058KB）. （4,515KB）. Agreement to acquire shares of Orchard Therapeutics.
